<DOC>
	<DOC>NCT00083421</DOC>
	<brief_summary>The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.</brief_summary>
	<brief_title>Effects of ONO-2506PO in Patients With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria Standardized MMSE Score of 13 to 24 points (inclusive) Modified Hachinski score equal or less than 4 Serious systemic disease that may preclude survival to study completion Other illnesses that may include dementive features</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>